8-K Announcements
6Material company update
May 18, 2026·SEC
Material company update
May 5, 2026·SEC
Material company update
Apr 21, 2026·SEC
Inotiv, Inc.(NOTV)Earnings, Financials & Key Ratios
NOTV•NASDAQ
$0.08
Price updated Jul 2, 2026
SectorHealthcareIndustryDiagnostics & ResearchSub-IndustryContract Research and Preclinical Services
AboutInotiv, Inc. provides drug discovery and development services to the pharmaceutical, chemical, and medical device industries; and sells analytical instruments to the pharmaceutical development and contract research industries. It operates through two segments, Contract Research Services and Research Products. The Contract Research Services segment offers screening and pharmacological testing, nonclinical safety testing, formulation development, regulatory compliance, and quality control testing services. This segment provides analytical method development and validation; drug metabolism, bioanalysis, and pharmacokinetics testing to identify and measure drug and metabolite concentrations in complex biological matrices; in vivo sampling services for the continuous monitoring of chemical changes in life; stability testing to ensure the integrity of various solutions used in nonclinical and clinical studies, and post-study analyses; non-clinical toxicology and pathology services; and climate-controlled archiving services for its customers' data and samples. The Research Products segment designs, develops, manufactures, and markets in vivo sampling systems and accessories, including disposables, training, and systems qualification; physiology monitoring tools; liquid chromatography and electrochemistry instruments platforms; analytical products comprising liquid chromatographic and electrochemical instruments with associated accessories; and in vivo sampling products consisting of Culex family of automated in vivo sampling and dosing instruments. The company operates in the United States, rest of North America, the Pacific Rim, Europe, and internationally. It has an agreement with BioVaxys to conduct preclinical toxicity studies for its Covid-T Immunodiagnostic program. The company was formerly known as Bioanalytical Systems, Inc. and changed its name to Inotiv, Inc. in March 2021. Inotiv, Inc. was founded in 1974 and is headquartered in West Lafayette, Indiana.Show more
- Revenue$513M+4.5%
- EBITDA$25M+185.4%
- Net Income-$69M+36.7%
- EPS (Diluted)-2.11+49.6%
- Gross Margin12.68%-44.0%
- EBITDA Margin4.88%+181.7%
- Operating Margin-6.02%+65.8%
- Net Margin-13.38%+39.5%
- ROE-44.78%+9.4%
NOTV Price & Volume
Inotiv, Inc. (NOTV) stock price & volume — 10-year historical chart
Loading chart...
Persistent Operational Losses Threaten Inotiv Financial Stability
Investment Thesis • Updated 2026Q2
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Liquidity and solvency distress
Key Thesis Takeaways
- Inotiv faces a precarious fundamental outlook characterized by persistent revenue contraction and severe margin compression, as evidenced by a 5.4% year-over-year decline in 2026Q2 revenue.
- The company's aggressive acquisition strategy has resulted in a deeply negative net margin of -27.6% and an alarming accumulation of debt, pushing the debt-to-equity ratio to 6.33.
- Investors should remain cautious as the firm struggles to achieve operational scale, with current liquidity levels appearing insufficient to support ongoing capital requirements.
Verdict Logic
the company's precarious liquidity position, reflected in a current ratio of 0.27, and persistent net losses of $32.5 million in 2026Q2 suggest significant solvency risks that outweigh potential valuation upside.
NOTV Growth Metrics
Inotiv, Inc. (NOTV) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years36.59%
5 Years53.36%
3 Years-2.15%
TTM5.61%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM0.57%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM20.69%
Return on Capital
10 Years-6.11%
5 Years-6.87%
3 Years-10.07%
Last Year-7.05%
NOTV Recent Earnings
Inotiv, Inc. (NOTV) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 4/12 qtrs (33%)●Beat Revenue 5/12 qtrs (42%)
Q2 2026Latest
May 11, 2026Metric
Actual
Est
EPS
$0.94-48.0%
$0.64
Rev
$118M-5.7%
$125M
Q1 2026
Feb 9, 2026Metric
Actual
Est
EPS
$0.72-12.9%
$0.64
Rev
$121M-0.0%
$121M
Q4 2025
Dec 3, 2025Metric
Actual
Est
EPS
$0.14-75.0%
$0.08
Rev
$138M+0.5%
$138M
Q3 2025
Aug 6, 2025Metric
Actual
Est
EPS
$0.12+20.0%
$0.15
Rev
$131M-2.0%
$133M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 11, 2026 | $0.94vs $0.64-48.0% | $118Mvs $125M-5.7% |
| Q1 2026 | Feb 9, 2026 | $0.72vs $0.64-12.9% | $121Mvs $121M-0.0% |
| Q4 2025 | Dec 3, 2025 | $0.14vs $0.08-75.0% | $138Mvs $138M+0.5% |
| Q3 2025 | Aug 6, 2025 | $0.12vs $0.15+20.0% | $131Mvs $133M-2.0% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Inotiv, Inc. (NOTV)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.08 | $2.79M | -0.04 | 4.54% | -13.38% | -44.78% | — | |
| $228.68 | $11.01B | -78.58 | -0.85% | -4.59% | -5.66% | — | |
| $81.57 | $9.68B | 31.86 | 37.55% | 23.13% | 126.27% | — | |
| $25.82 | $1.02B | 161.38 | 3.63% | 1.27% | 1.31% | — | |
| $168.72 | $12.92B | 58.18 | -0.37% | 5.35% | 4.7% | — | |
| $546.29 | $15.6B | 35.75 | 19.97% | 17.19% | 120.89% | — |
Compare NOTV vs Peers
Inotiv, Inc. (NOTV) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
NOTV SEC Filings & Documents
Inotiv, Inc. (NOTV) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when NOTV posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
NOTV Frequently Asked Questions
Inotiv, Inc. (NOTV) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Inotiv, Inc.'s revenue?
Inotiv, Inc. (NOTV) reported $507.4M in revenue for fiscal year 2025. This represents a 3305% increase from $14.9M in 1997.
How fast is Inotiv, Inc. growing?
Inotiv, Inc. (NOTV) grew revenue by 4.5% over the past year. Growth has been modest.
Is NOTV profitable?
Inotiv, Inc. (NOTV) reported a net loss of $87.0M for fiscal year 2025.
Dividend & Returns
What is NOTV's return on equity?
Inotiv, Inc. (NOTV) has a return on equity (ROE) of -44.8%. Negative ROE indicates the company is unprofitable.
What is Inotiv, Inc.'s free cash flow?
Inotiv, Inc. (NOTV) had negative free cash flow of $13.6M in fiscal year 2025, likely due to heavy capital investments.